Nuveen
BMRN icon

Nuveen’s BioMarin Pharmaceuticals BMRN Stock Holding History

Nuveen’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-59,200
Closed -$5K – 3369
2020
Q4 		$5K Buy
+59,200
New +$4.69M ﹤0.01% 3265

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nuveen's BMRN Position: Q2 2026 in Review

Nuveen reduced its BioMarin Pharmaceuticals (BMRN) stake by 2.3% in Q2 2026, selling an estimated $880K and leaving 689,131 shares worth $39.4M. The position accounts for 0.01% of the portfolio, ranked #846.

Nuveen first reported a position in BMRN in Q2 2013 and has held it in 43 quarters since. The position peaked at $381M in Q2 2020. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Nuveen held 689,131 shares of BioMarin Pharmaceuticals worth $39.4M as of Q2 2026.
  • Nuveen sold 16,067 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $880K.
  • BioMarin Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #846 holding.
  • Nuveen first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • Nuveen's BioMarin Pharmaceuticals position peaked at $381M in Q2 2020.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.